Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 134

recruiting
3 982
countries
28
conditions
2 106

2 730 trials match your criteria

Ocular myasthenia

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Obesity

Not recruiting

Study on Maintaining Weight Loss in Teens with Obesity Using Semaglutide

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Semaglutide

Cortical dysplasia+1

Not recruiting

Study on the Safety and Effectiveness of Sirolimus for Treating Drug-Resistant Epilepsy in Children with Rare Brain Disorders Linked to mTOR Pathway Activation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sirolimus

Study of Avelumab and Axitinib for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors After Standard Therapy Failure

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Untreated Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab

Mastocytosis

Not recruiting

Study on the Effectiveness and Safety of Masitinib for Patients with Severe Systemic Mastocytosis Unresponsive to Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant

Multiple sclerosis

Not recruiting

Study on Masitinib for Treating Primary or Secondary Progressive Multiple Sclerosis in Patients Without Relapse

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.